This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cramer's 'Mad Money' Recap: July 10

Click here for an archive of Cramer's "Mad Money" recaps.


"Healthcare stocks have nothing to fear," Jim Cramer told viewers of his "Mad Money" TV show Thursday.

He reiterated his belief that the healthcare sector is the place to be given the current market conditions. He expects big money managers to flock to the historically recession-proof stocks and advised investors to get in ahead of the rotation.

Cramer recommended Hospira (HSP - Get Report) as his next investment idea in the group. Hospira, he said, is transforming itself from a boring drug delivery and medication management company into a faster growing, higher-margin oncology powerhouse.

Hospira was spun off by Abbott Labs (ABT) back in 2004, and after a rocky start, Cramer said, the company is finally starting to gain some traction. The company has met or beat earnings expectations for the past seven quarters in a row, giving it a solid track record of results, he said.

Hospira is currently the No. 1 maker of specialty injectable pharmaceuticals, with 17% market share in the U.S. The company also has real potential for growth in Japan, where generic drug use by the government-run healthcare system accounts for only 16% of all drugs used, compared to 50% in the U.S.

Cramer is especially high on Hospira's injectable oncology division, after the company's purchase of Mayne Pharmaceuticals in February, 2006. This business, he said, provides Hospira growth that Wall Street has failed to notice.

Cramer: The Tide's Turned for Drug Stocks
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CHK $8.66 0.00%
GTS $21.58 0.00%
HSP $89.45 0.00%
HUM $182.09 0.00%
HNT $66.86 0.00%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs